Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-020-00917-y
Keywords
Cancer immunotherapy; Co-inhibition; Co-stimulation; Immune checkpoint; VISTA
Categories
Funding
- National Natural Science Foundation of China [31970696, 81502975]
- National Key Research and Development Program [2019YFC1316000]
- China Postdoctoral Science Foundation [2016 T90413, 2015 M581693]
Ask authors/readers for more resources
VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized. Here, we review the current knowledge on the therapeutic phenotypes and molecular mechanisms that underlie the contradictory roles of VISTA in checking anti-cancer immune responses. Furthermore, we highlight the potential indeterminacy of VISTA-targeted strategies in cancer immunotherapy, with in silico analyses. In fact, VISTA functions like a homeostatic regulator that actively normalizes immune responses. Thus, the regulatory role of VISTA in anti-cancer immunity remains to be fully elucidated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available